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Severe acute respiratory syndrome (SARS) coronavirus (SARS-CoV) caused a severe outbreak in several regions of the world in 2003. The
SARS-CoV genome is predicted to contain 14 functional open reading frames (ORFs). The first ORF (1a and 1b) encodes a large polyprotein that
is cleaved into nonstructural proteins (nsp). The other ORFs encode for four structural proteins (spike, membrane, nucleocapsid and envelope) as
well as eight SARS-CoV-specific accessory proteins (3a, 3b, 6, 7a, 7b, 8a, 8b and 9b). In this report we have cloned the predicted nsp8 gene and
the ORF6 gene of the SARS-CoV and studied their abilities to interact with each other. We expressed the two proteins as fusion proteins in the
yeast two-hybrid system to demonstrate protein–protein interactions and tested the same using a yeast genetic cross. Further the strength of the
interaction was measured by challenging growth of the positive interaction clones on increasing gradients of 2-amino trizole. The interaction was
then verified by expressing both proteins separately in-vitro in a coupled-transcription translation system and by coimmunoprecipitation in
mammalian cells. Finally, colocalization experiments were performed in SARS-CoV infected Vero E6 mammalian cells to confirm the nsp8–
ORF6 interaction. To the best of our knowledge, this is the first report of the interaction between a SARS-CoVaccessory protein and nsp8 and our
findings suggest that ORF6 protein may play a role in virus replication.
© 2007 Elsevier Inc. All rights reserved.Keywords: SARS coronavirus; Protein–protein interaction; Yeast two-hybrid system; Non structural protein; Accessory protein; ImmunoprecipitationIntroduction
Severe acute respiratory syndrome (SARS) is a newly
emerging infectious disease. The etiologic agent of SARS has
been identified as a novel coronavirus, namely SARS-associated
coronavirus (SARS-CoV) (Ksiazek et al., 2003; Marra et al.,
2003; Peiris et al., 2003; Rota et al., 2003). As of June 30th,
2003, 8447 probable SARS cases including 811 deaths were
reported by the World Health Organization (WHO) from 32Abbreviations: AD, activation domain; BD, binding domain; 3-AT, 3-amino
trizole; N, nucleocapsid.
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0042-6822/$ - see front matter © 2007 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2007.04.029countries or regions worldwide. The significant morbidity and
mortality, and the potential for re-emergence, makes SARS-CoV
a continued worldwide public health threat.
Like other known coronaviruses, SARS-CoV is an envel-
oped, plus-strand RNA virus that features the largest RNA
genomes currently known. The SARS viral genome comprises
approximately 30,000 nucleotides, which are organized into 14
functional open reading frames (ORFs) (Rota et al., 2003; Thiel
et al., 2003). Analysis of the nucleotide sequence of this novel
coronavirus revealed a similar pattern of gene organization
typical of coronaviruses (Marra et al., 2003; Rota et al., 2003).
Two large, 5′-terminal overlapping ORFs, 1a and 1b of the
replicase gene encode two polyproteins, pp1a and pp1ab (Fig. 1)
(Rota et al., 2003; Thiel et al., 2003). Like other coronaviruses,
the nascent SARS-CoV replicase polyproteins are processed by
Fig. 1. Cloning of the putative nsp8 and ORF6 genes from the SARS CoV genome. The full-length nsp8 (198 amino acids) and ORF6 (66 amino acids) genes of the
SARS coronavirus (Tor2 isolate) were PCR-amplified from a genomic construct of clone NC_004718 and cloned into the pCR-XL-TOPO vector (Invitrogen) as
described in Table 1. The scale on top shows genomic region.
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have been identified: a 3C-like proteinase (3CLpro) and a
papain-like proteinase (PLP) (Denison et al., 1992; Snijder et
al., 2003; Ziebuhr, 2004). The processed end products of pp1a
are designated nonstructural proteins (nsp) 1 to nsp11 and those
of pp1ab are designated nsp1 to nsp16. Cleavage by the viral
main protease, 3CLpro results in generating the nsp8 protein
which is currently of undesignated function. The nsp8 protein
has been shown to associate with several other nsps and to
colocalize with these nsps in cytoplasmic complexes that are
important for viral RNA synthesis (Prentice et al., 2004a,
2004b; Sutton et al., 2004; Zhai et al., 2005). The +RNA
coronavirus usually encode a non-structural protein (nsp12 for
SARS-CoV) that includes an RdRp domain, conserved in all
RNAviruses. The SARS-CoV uniquely encodes a second RdRp
residing in nsp8, responsible for initiation of the synthesis of
complementary oligonucleotides smaller than 6 residues long,
at relatively low fidelity. These nsp8 RdRp produced primers
are postulated to be utilized by the primer-dependent nsp12
RdRp for replication (Imbert et al., 2006).
The remaining 12 ORFs encode the four structural proteins,
spike (S), membrane (M), nucleocapsid (N) and envelope (E),
and eight accessory proteins (3a, 3b, 6, 7a, 7b, 8a, 8b and 9b).
These accessory proteins are postulated to be non-essential in
tissue culture but may provide a selective advantage in the
infected host. The ORF3a protein has been studied to some
details (Tan et al., 2006) and has been shown to be expressed in
infected cells (Tan et al., 2004c; Yu et al., 2004; Zeng et al.,
2004). ORF3a protein has been shown to bind the spike protein
(Zeng et al., 2004; Tan et al., 2004c) and recent work
demonstrated that it is a novel structural protein (Ito et al.,
2005). The ORF7a protein was also detected in infected cells
and has been found to localize in the ER-Golgi intermediate
compartments where coronaviruses are known to assemble
(Fielding et al., 2004; Nelson et al., 2005). In addition, ORF3a,
ORF3b and ORF7a proteins have been shown to induceapoptosis (Tan et al., 2004a; Law et al., 2005; Yuan et al., 2005).
Two recent papers on the ORF6 accessory protein also
demonstrated its expression during infection and have showed
that it may be important for viral pathogenesis (Geng et al.,
2005; Pewe et al., 2005). Most recently the ORF6 protein has
been shown to accelerate replication of a related mouse virus, a
property that may contribute towards its increased in vivo
virulence (Tangudu et al., 2007).
In this study, the nsp8 and ORF6 proteins were tested for
interaction in a yeast cellular environment using the yeast two-
hybrid system. These interactions were further verified by in-
vitro coimmunoprecipitation experiments using proteins
expressed by a coupled-transcription/translation system or in
mammalian cells by lipid-mediated transfection of DNA.
Finally, the nsp8–ORF6 interaction was confirmed by coloca-
lization of the two proteins in SARS-CoV infected mammalian
cells (Vero E6). This unique SARS-CoV accessory protein 6
interacting with a non-structural protein, nsp8, suggests that
ORF6 may have a role in SARS virus replication.
Results and discussion
The nsp8 protein of the SARS coronavirus was cloned from
the Tor2 Singapore isolate and expressed using the yeast two-
hybrid vectors resulting in an N-terminal in-frame fusion
protein with the GAL4 activation domain (AD). Similarly the
ORF6 protein was PCR cloned and expressed in yeast two-
hybrid vectors resulting in an N-terminal in-frame fusion
protein with the GAL4 DNA binding domain (BD). In order to
check for correct reading-frame constructs, the final plasmids
were sequenced and checked for in-vitro protein expression.
Saccharomyces cerevisiae AH109 cells were transformed with
single plasmids, or co-transformed with the GAL4 BD- and
AD-vectors containing SARS Co-V ORF6 and/or nsp8,
respectively. The AH109 host strain containing pAS2-N and
pACT2-N were used as positive controls (Surjit et al., 2004).
295P. Kumar et al. / Virology 366 (2007) 293–303AH109 contains integrated copies of both HIS3 and lacZ
reporter genes under the control of GAL4 binding sites. The
results of the two-hybrid assay are shown in Fig. 2A. Single
transformants used in this assay were yeast (AH109) cellsFig. 2. Yeast two-hybrid results showing that nsp8 and ORF6 proteins interact with
single and co-transformants on various synthetic growth media lacking specific am
strain. SDTrp− and SD-Leu− selective media have Tryptophan and Leucine mis
Tryptophan, Leucine and Histidine. Growth on the SD Trp−Leu−His− plate and blue c
interaction. BD-N:AD-N combination was used as a positive control in these yeast
results of the nsp8–ORF6 protein–protein interactions. Single transformants and co-t
each other. Values given are in arbitrary units. The numbers above each bar repre
untransformed host strain. Transformants with more than one plasmid are separated by
(Harper et al., 1993). (C) Measurement of strength of the nsp8–ORF6 interactions on
the host AH109 strain, single transformants (BD, AD, BD-ORF6 and AD-nsp8), and
dilutions of all of the above-mentioned log-phase cultures were plated on YPD (left
5 mM 3-AT).containing BD-ORF6, and host cells containing AD-nsp8, also
yeast cells containing only the BD- and only the AD-vectors,
were also used as negative controls. All these transformants and
co-transformants grew well on the unrestricted YPD plate (non-each other. (A) AD-nsp8 fusion protein and BD-ORF6 fusion protein tested as
ino-acids. YPD media shows uninhibited growth of all transformants and host
sing, respectively. SD Trp−Leu−His− media are triple dropout plates lacking
olor (shown here in shades of grey) on the β-gal filter assay represents a positive
two-hybrid experiments (Surjit et al., 2004). (B) Liquid β-galactosidase assay
ransformants were analyzed in a liquid β-galactosidase assay and compared with
sent the mean from five independent transformants. Y187 corresponds to the
a slash. Positive controls used in this assay are denoted by BD-SNF1/AD-SNF4
an increasing 3-AT gradient. Activation of the HIS3 reporter was determined for
co-transformants (BD-ORF6/AD-nsp8 and BD-N/AD-N). Hundred-fold serial
) followed by SD-His-plus 50 mM 3-AT in increasing concentrations (0 mM to
296 P. Kumar et al. / Virology 366 (2007) 293–303selective media). Also, the untransformed host cells were plated
as a negative control. Single transformants containing the BD-by
itself or as a fusion with the ORF6 protein, showed growth on the
synthetic dextrose Trp− plate (SDTrp−). Correspondingly, single
transformants containing the AD- by itself or as a fusion with
nsp8 showed growth on the synthetic dextrose Leu− plate
(SDLeu−). The co-transformants were similarly plated on YPD
and synthetic dextrose medium lacking Trp or Leu or Trp, Leu
and upon positive growth on these was subsequently plated on
His− medium (SD Trp−Leu−His−) to test for His prototrophy.
Growth of the co-transformants, containing the BD-ORF6 and
AD-nsp8 constructs, in both SDTrp− and SDLeu− plates simply
showed that both plasmids were present in the transformed cells.
Growth of these clones on the SD Trp−Leu−His− media showed
that the transcription of the HIS3 gene was turned on by the
reconstitution of the GAL4 transactivator due to a specific
ORF6–nsp8 interaction. Colonies were transferred on to
nitrocellulose filters and a β-galactosidase filter assay was per-
formed as described in methods. The co-transformants contain-
ing both the BD-ORF6 and AD-nsp8 constructs along with all
positive and negative controls were used in this assay. Results
obtained from the β-galactosidase filter assay were in
agreement with the results obtained from the SDHis− growth
experiments.
The liquid β-galactosidase assay was conducted and the
activity determined using the substrate chlorophenol red-β-D-
galactopyranoside (CPRG) as described in methods. The host
strain alone, along with single transformants containing either
AD-nsp8 or BD-ORF6 and co-transformants containing AD-/
BD- without a fusion protein was tested. Negative controls (host
untransformed cells) showed almost no liquid β-galactosidaseFig. 3. Confirmation of the nsp8–ORF6 interaction using an in-vitro cell-free coupled
and myc-tagged ORF6 proteins were produced by coupled transcription–translation
(Anti-His and anti-myc, respectively). Both nsp8 and ORF6 proteins were visible a
respectively. (B) The 35S-Met-His-nsp8 and 35S-Met-myc-ORF6 proteins were detect
and anti-myc antibodies on 16% SDS-PAGE. When nsp8 was probed for using anti-
using myc antibody, the nsp8 protein was visible. (C) In a control reaction, the 35S-M
the other antibody used in the pull-down experiments. Also this control experiment sh
shown in panel B. Lane 1 shows the nsp8 protein immunoprecipitated by anti-His, l
Similarly, lane 3 shows myc-tagged ORF6 protein immunoprecipitated by anti-myc
anti-His.activity. BD-SNF1/AD-SNF4 was the positive control whereas
the clones containing BD-ORF6/AD-nsp8 were the test samples
in this experiment (Fig. 2B). Relative enzymatic activity was
determined in five independent transformants from each group.
Our results from this assay indicate a moderate strength
protein–protein interaction between the AD-nsp8 and BD-
ORF6 proteins. This observation was further confirmed by the
use of a 3-AT gradient on which the His+ phenotype was tested
(Fig. 2C). 3-AT is known to be a competitive inhibitor of HIS3
protein, thus enhancing the stringency of selection, it reduces
the background signal by inhibiting the product of the HIS3
reporter. This result clearly showed that the interaction of nsp8
with ORF6 was not as strong as the N–N dimerization positive
control interaction. On plates with increasing concentrations of
3-AT, the growth ability of the His+ colonies diminished and
was almost undetectable at 5 mM 3-AT concentrations.
To further confirm these interactions we performed a
coimmunoprecipitation assay using proteins expressed by a
cell-free coupled transcription–translation system. The rabbit
reticulocyte lysates expressing His6-nsp8 and myc-ORF6
proteins separately were tested for expression (Fig. 3A). For
detection of the expressed proteins, the lysates were immuno-
precipitated using the respective antibodies i.e. anti-His
antibody was used for detection of the nsp8 protein and anti-
myc antibody was used for the detection of the ORF6 protein.
When the two cell lysates were mixed in equal proportions, one
of the two antibodies was added and subsequently pulled out
using Protein A Sepharose beads, we observed the interacting
protein to be present in the gel as well. This procedure was
repeated conversely to show the other corresponding antibody
pull out the interacting protein partner as well (Fig. 3B). Whentranscription/translation coimmunoprecipitation assay. (A) The His6-tagged nsp8
in the presence of 35S-Met and detected using their corresponding antibodies
nd corresponded to their correct molecular sizes on 12% and 20% SDS-PAGE,
ed by autoradiography. The nsp8–ORF6 complex was detected by both anti-His
His antibody, the ORF6 protein was visible and when ORF6 protein was probed
et-His6-nsp8 and
35S-Met-myc-ORF6 proteins showed no cross-reactivity with
ows that the proteins do not non-specifically bind to the beads used in the results
ane 2 does not show nsp8 protein band when immunoprecipitated by anti-myc.
and lane 4 does not show ORF6 protein where it was immunoprecipitated using
Fig. 4. (A) Cell lysates were obtained from Vero E6 cells expressing ORF6 and
myc-nsp8 or ORF6 and myc-GST (negative control) and subjected to Western
blot analysis with either anti-ORF6 polyclonal (upper panel, lanes 1 and 2) or
anti-myc monoclonal antibodies (lower panel, lanes 1 and 2). Equal amounts of
lysates were subjected to immunoprecipitation using anti-myc polyclonal
antibodies and protein A beads. The immuno-complexes were subjected to
Western blot with either anti-ORF6 polyclonal (upper panel, lanes 3 and 4) or
anti-myc monoclonal antibodies (lower panel, lanes 3 and 4). (B) Equal amounts
of total cellular protein from Vero E6 cells either uninfected (lane 1) or infected
with wildtype Dryvax (lane 2), a recombinant vaccinia virus expressing the
SARS-CoV S protein (lane 3), or the recombinant vaccinia virus expressing the
ORF6 protein used in this study (lane 4) were subjected to Western blot and
probed with anti-ORF6 rabbit polyclonal antibody. This demonstrates that the
∼37 kDa band seen in lanes 1 and 2 of panel A is a cross-reacting protein that is
probably a vaccinia virus protein or an up-regulated cellular protein which is
detected by the rabbit anti-ORF6 antibody used in this study.
Fig. 5. Lysates were obtained from SARS-CoV infected Vero E6 cells harvested
at 0 or 24 h post infection (h.p.i.) and Western blot analyses were performed to
determine the expression of SARS-CoV proteins using mouse anti-nsp8 mono-
clonal antibody (upper panel, lanes 1 and 2) and rabbit anti-ORF6 polyclonal
antibody (lower panel, lanes 1 and 2). Cell lysates obtained at 24 h.p.i. were then
subjected to immunoprecipitation using anti-Flag (irrelevant antibody as nega-
tive control) or anti-ORF6 rabbit polyclonal antibodies and protein A beads. The
immuno-complexes were subjected to Western blot analysis with mouse anti-
nsp8 monoclonal antibody (upper panel, lanes 3 and 4).
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mixture of proteins, it also pulled out the ORF6 protein.
Similarly, when anti-myc antibody was used to pull out the
ORF6 protein, the nsp8 protein was also observed to be pulled
out as an interaction partner of ORF6. In a control experiment
we observed no ORF6 protein binding directly to the anti-His
antibody Sepharose-A complex and similarly observed no
binding of the nsp8 protein to the anti-myc antibody Separose-A
complex (Fig. 3C). These results clearly showed that the two
proteins nsp8 and ORF6 interacted with each other.
In order to verify the interaction between nsp8 and ORF6
in mammalian cells, co-immunoprecipitation experiments
were performed using lysates obtained from Vero E6 cellsexpressing transiently transfected myc-tagged nsp8 and
untagged ORF6 proteins carried by a replicative recombinant
vaccinia virus. Myc-polyclonal antibody conjugated to protein
A Sepharose beads was used to pull-down myc-nsp8 or myc-
GST (negative control), and any ORF6 protein that co-
immunoprecipitated was detected using a rabbit polyclonal
antibody raised against a peptide of ORF6 (Abgent). This anti-
body specifically detected the ORF6 protein (∼7 kDa) in cells
that were infected with ORF6 recombinant vaccinia virus (Fig.
4, lanes 1 and 2). As shown in Fig. 4, ORF6 was co-immuno-
precipitated by myc-nsp8 (lane 3) but not by myc-GST (lane 4),
showing that the ORF6 and nsp8 proteins can interact in Vero
E6 cells.
In order to confirm that the interaction between nsp8 and
ORF6 occurs during SARS-CoV infection, co-immunoprecipi-
tation experiments were performed with lysates obtained from
SARS-CoV infected cells. Infection of Vero E6 cells with an
isolate of SARS-CoV (strain HKU 39849) was carried out in a
physical containment level 4 (PC4) laboratory as previously
described (Kaye et al., 2006). The cells were harvested at 0 or
24 h post-infection (h.p.i.) and the lysates were subjected to
Western blot analysis to determine the expression of nsp8 and
ORF6 proteins (Fig. 5). Two specific proteins in the cells at 24 h.
p.i. were detected with purified supernatant from hybridomas
producing monoclonal antibodies against the nsp8 protein (see
Materials and methods) and these were not found in the cells
harvested at 0 h.p.i. (upper panel, lanes 1 and 2). The protein that
298 P. Kumar et al. / Virology 366 (2007) 293–303migrated at ∼24 kDa matched the predicted molecular mass of
nsp8 while the slower migrating protein (∼65 kDa) may be an
aggregated form of nsp8. As expected, the ORF6 protein was
also detected at 24 h.p.i. and not at 0 h.p.i. (lower panel, lanes 1
and 2). Cell lysates obtained at 24 h.p.i. were then subjected to
immunoprecipitation with either an irrelevant antibody (rabbit
anti-Flag polyclonal antibody, lane 3) or rabbit anti-ORF6
polyclonal antibody (lane 4) and protein-A agarose beads.
Western blot analyses showed that nsp8 protein (∼24 kDa) was
co-immunoprecipitated when anti-ORF6 antibody was used but
not when an irrelevant antibody was used, indicating that the
nsp8 interacts specifically with ORF6 in SARS-CoV infected
cells (upper panel, lanes 3 and 4).
Indirect immunofluorescence analysis of ORF6 expression
in SARS-CoV-infected cells (Fig. 6, middle panel) showed
that, consistent with previous publications (Geng et al., 2005;
Pewe et al., 2005), ORF6 was found in the cytoplasm. Most of
the ORF6 protein seen in infected cells were observed in a
punctate staining pattern consistent with a vesicle-associated
intracellular distribution. Using the rabbit polyclonal antibody
against ORF6 (Abgent) and purified supernatant from hy-
bridomas producing monoclonal antibodies against the nsp8
protein (see Materials and methods), cells infected with an
isolate of SARS-CoV (strain HKU39849) were examined byFig. 6. Indirect immunofluorescence used to study cellular localization of nsp8 and O
and rabbit anti-ORF6 (B) antibodies were used against uninfected cells to determine i
of a DAPI stain (C). (Middle panel) Vero E6 cells infected with SARS-CoVwere exam
of nsp8 is represented by FITC staining (E), while the expression of ORF6 is represen
(G). The merged image showed that the nsp8 and ORF6 proteins colocalize to punct
anti-GAL4TA (I) and rabbit anti-flag (J)) were used to probe SARS-CoV infected cells
the specificity of the antibodies used in detecting the ORF6 and nsp8 proteins.indirect immunofluorescence to determine if the two proteins
colocalized, as their interaction would suggest. The extent of
colocalization seen between the two proteins was significant,
both localizing to the same set of punctate structures (Fig. 6,
middle panel, D). The punctate distribution of nsp8 has been
previously described (Prentice et al., 2004a) and the
colocalization of ORF6 protein with nsp8 suggests that
ORF6 could be associated with the SARS-CoV replicase
complex, localized to a subset of the vesicular trafficking
complex in mammalian cells. These ORF6-containing vesi-
cular structures did not colocalize with AP-1 and LAMP-2
(data not shown), which are present in early and late
endosomes respectively. However, the ORF6 protein does
colocalize with LAMP-1 (Fig. 7), which is a lysosomal
marker. LAMP-1 has been used as a marker for characteristic
double-membrane vesicles seen in infections by other viruses
(Jackson et al., 2005) and it has been shown that at least one
other coronavirus induces these double-membrane vesicles,
presumably as a site for the assembly of virus replication
complexes (Prentice et al., 2004b). Given this, the ORF6
protein might localize to these vesicles which have been
suggested to be derived from the cellular autophagosomal
machinery, but further study will be required. A recent struc-
tural study of the nsp8 protein has suggested a role for theRF6 in SARS-CoV infected Vero E6 cells. (Upper panel) Mouse anti-nsp8 (A)
f the antibodies showed any unspecific staining. Nuclei are represented by means
ined by indirect immunofluorescence using the same antibodies. The expression
ted by Rhodamine staining (F). Nuclei are represented by means of a DAPI stain
uate structures in the cytoplasm (H). (Lower panel) Irrelevant antibodies (mouse
at the same final concentrations as their counterparts in the middle panel to show
Table 1
Yeast strains, plasmids and recombinant plasmid constructs used in this study
Strain/plasmid/
construct
Genotype/description/reference
Strains
AH109 MATa trp1-901 his3 leu2-3, 112 ura3-52 ade2 gal4
gal80URA3∷GAL-lacZ LYS2∷GAL-HIS3
Y187 MATα, ura3-52, his3-200, ade2-101, trp1-901, leu2-3, 112,
gal4Δ, met-, gal80Δ, URA3∷GAL1UAS- GAL1TATA-lacZ
Plasmids
pGADT7/pACT2 GAL4 AD vector [GAL4(768–881)]; LEU2, 2 μm, Ampr
pGBKT7/pAS2 GAL4 DNA-BD vector [GAL4(1–147)]; TRP1, 2 μm, Ampr
Constructs
pACT2-nsp8 pCR-XL-TOPO-nsp8-easy-nsp8 digested with NcoI and
EcoRI, fragment ligated into pACT2
pGBKT7-ORF6 pCR-XL-TOPO-ORF6 digested with NcoI and EcoRI,
fragment ligated into pGBKT7
pRSET-nsp8 pGEMT-nsp8 digested with NcoI and EcoRI,
fragment ligated into pRSET
Fig. 7. Indirect immunofluorescence was used to probe for LAMP-1 (A, E) and ORF6 (B, F) staining in SARS-CoV infected cells (upper panel) and uninfected Vero E6
cells (lower panel). Nuclei are represented by means of a DAPI stain (C, G). The merged image showed that there is colocalization between the LAMP-1 protein and
ORF6 proteins in SARS-CoV infected cells (D, upper panel).
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the viral replication cycle (Zhai et al., 2005), further lending
impetus to such a study.
This is the first report describing the interaction between
the ORF6 accessory protein and the nsp8 protein. We
demonstrated the strength and specificity of this interaction
by three independent methods, i.e. by yeast-2-hybrid, co-
immunoprecipitation using in-vitro translated proteins in a
cell-free system and co-immunoprecipitation using lysates
from Vero E6 cells. Interestingly, two previous publications
on ORF6 have shed some light on its possible function in
viral pathogenesis. Geng and co-workers detected ORF6
protein in lung and intestine of SARS patients and showed
that it could stimulate cellular DNA synthesis when over-
expressed (Geng et al., 2005). Pewe et al. (2005) showed that
when SARS-CoV ORF gene was introduced into an
attenuated murine coronavirus, the recombinant virus grew
faster in cell culture and also exhibited enhanced lethality of
infection in mice. In contrast, Yount and co-workers reported
that the SARS-CoV virus with ORF6 deleted has the same
viral replication kinetics as the wild-type virus in cell-culture
and mice (Yount et al., 2005). Hence, ORF6 is non-essential
for viral replication in these models although it cannot rule
out that ORF6 (and/or the other accessory proteins of SARS-
CoV) contributes to the virulence and pathogenesis of SARS
coronavirus infection in its natural host. Further experiments
in more robust animal models, like non-human primates that
demonstrate clinical disease upon SARS-CoV infection, will
be needed to determine the actual function of ORF6 during
SARS infection in vivo. Since our data shows that ORF6
interacts with nsp8 which is part of the replicase complex
(Prentice et al., 2004a, 2004b), it will be important in future
studies to determine if the interaction between ORF6 and
nsp8 can modulate the viral synthesis process and to
determine how ORF6 modulates viral pathogenesis in these
animal models.Materials and methods
Growth media, yeast strains and plasmid constructs
All strains, plasmids and plasmid constructs used in this
study are described in Table 1. The full-length nsp8 and ORF6
genes of the SARS coronavirus (Tor2 isolate) were PCR-
amplified from a genomic construct of clone NC_004718
(Fig. 1), and cloned into the pCR-XL-TOPO vector
(Invitrogen). The full-length nsp8 and ORF6 genes were
subjected to DNA sequencing and the inserts were verified
against the corresponding region of the SARS coronavirus
complete genome NC_004718. The nsp8 gene was excised
from the pCR-XL-TOPO-nsp8 construct using the restriction
enzymes NcoI and EcoRI, and ligated into the yeast two-
300 P. Kumar et al. / Virology 366 (2007) 293–303hybrid Activation Domain vector, pACT2 to generate an N-
terminal in-frame fusion with the GAL4 activation domain
(AD). The ORF6 gene was excised from the pCR-XL-
TOPO-ORF6 construct using the restriction enzymes EcoRI
and PstI, and cloned into the yeast two-hybrid DNA Binding
Domain (BD) vector pGBKT7 in fusion with the GAL4
DNA-binding domain to express an N-terminal fusion
protein. Similarly the NcoI and EcoRI sites were used to
clone the nsp8 gene into the pRSET vector to give the
construct pRSET-nsp8. All DNA manipulations were per-
formed as described by Sambrook et al. (1989). All
constructs were verified by restriction digestion and DNA
sequencing.
Yeast two-hybrid techniques
The GAL4-based two-hybrid system, kindly provided by
Dr. Stephen Elledge (Harper et al., 1993), containing pGBKT7
(DNA-binding domain vector) and pACT2 (activation domain
vector), together with the yeast reporter strain S. cerevisiae
AH109 (trp1-901 his3 leu2-3, 112 ura3-52 ade2 gal4
gal80URA3∷GAL-lacZ LYS2∷GAL-HIS3) were employed.
The host strain containing the Nucleocapsid protein (N) of
SARS virus fusion constructs pACT2-N and pAS2-N, shown
previously to form a homodimer (Surjit et al., 2004) was used
as a positive control. The AH109 host contains integrated
copies of both HIS3 and lacZ reporter genes under the control
of GAL4 binding sites. The AH109 yeast strain was
transformed with the appropriate plasmids, using the lithium
acetate procedure and grown on SD plates in the absence of
Trptophane (Trp) and Leucine (Leu); (SDTrp− and SDLeu−).
Protein interaction was tested on SD plates without Leu, Trp
and Histidine (SDLeu− Trp− His−). After 3 days at 30 °C,
individual colonies were streaked out and tested for liquid and
filter-lift β-galactosidase activity, 5 mM 3-amino-1,2,3-trizole
assay (3AT) and the liquid β-galactosidase assay (Ober et al.,
2002; Peiris et al., 2003; Pewe et al., 2005). The filter β-
galactosidase assay, a parameter directly reflecting the strength
of protein–protein interactions, was performed by streaking
doubly transformed yeast colonies onto filter paper and
allowing them to grow for 2 days on selection medium.
Yeast was permeabilized by freezing yeast-impregnated filters
in liquid nitrogen, and thawing at room temperature. This filter
was placed over a second filter that was pre-soaked in Z buffer
(pH 7.0) containing 10 mg/ml 5-bromo-4-chloro-3-indolyl-β-
D-galactopyranoside (X-gal) and 0.27% β-mercaptoethanol.
Filters were left for 18 h to develop a blue color, which
indicated a positive protein–protein interaction. The liquid β-
galactosidase activity was determined using the substrate
CPRG as described previously (Tyagi et al., 2001, 2002).
Relative enzymatic activity was determined in five indepen-
dent transformants. Data for quantitative assays were collected
for yeast cell number and are the mean±S.E.M. of triplicate
assays. Appropriate positive/negative controls and buffer
blanks were used. The yeast Y187 host strain containing
BD-1111 and AD-1112 were used as positive controls for
these assays.In-vitro cell-free coupled transcription/translation binding
analysis
The 35[S]-methionine labeled full-length pRSET-His6-nsp8
protein (198 amino acids nsp8 with N-terminal His6-tag) and
radiolabelled 35[S]-methionine full-length ORF6 accessory
protein (66 amino acids with an N-terminal myc tag), were
expressed in separate reactions using a coupled in-vitro
transcription–translation system (TNT coupled reticulocyte
lysate system; Promega) as per manufacturer's instructions.
10 μl of the His6-nsp8 labeled protein lysate was mixed with
10 μl of myc-ORF6 protein lysate. This mixture was incubated
on ice for 2 h and the primary antibody (either anti-His or anti-
myc) was added to the mixture. Subsequently the mixture was
incubated at 4 °C for 1 overnight. Sepharose-A beads were
added to the mixture and incubated at 4 °C with gentle shaking
for 1 h. The beads were washed three times with PBS,
resuspended in 10 μl of SDS-PAGE loading buffer and boiled
for 5 min to dissociate the bound proteins and detected by
autoradiography. Appropriate control reactions were performed
to validate the data.
Mammalian cell cultures
The CV-1 (African Green monkey kidney) cell-line was a
kind gift from Baxter Vaccines, Orth/Donau, Austria. The Vero
E6 cell-line was purchased from the American Type Culture
Collection (Manassas, VA, USA). All cells were cultured at
37 °C in 5% CO2 in DMEM containing 1 g/l glucose, 2 mM L-
glutamine, 1.5 g/l sodium bicarbonate, 0.1 mM non-essential
amino acids, 0.1 mg/ml streptomycin and 100 U penicillin, and
10% FBS (HyClone, Utah, USA).
Generation of ORF6 recombinant replicating vaccinia virus
ORF6 recombinant replicating vaccinia virus was generated
using the system developed by Baxter Vaccine (Orth/Donau,
Austria). The vector, cell-lines and viruses used here were kind
gifts from Baxter Vaccine. ORF6 was amplified from cDNA
prepared from SARS-CoV infected cells as previously
described (Tan et al., 2004b) and the pair of primers used is
ORF6_forward (5′-GCAAGCTTATGTTTCATCTTGTTGA-3′)
and ORF6_reverse (5′-CCGGCGGCCGCTTATGGATAATC-
TAACACC-3′). The amplicon was digested with HindIII and
NotI and cloned into the compatible sites of the pDD4-mh5
vector to create plasmid pDD4-mh5/ORF6. The pDD4-mh5
vector can be used to generate growth-competent recombinants
expressing foreign genes in the D4 locus via a rescue method as
previously described (Holzer and Falkner, 1997). Essentially,
the parental virus lacking the D4 gene is replication negative in
the usual permissive host lines and only the reintegration of D4
into the virus genome allows for growth in these lines. This is in
contrast to classical drug-based screening approaches which
have previously been well established in the generation of
vaccinia recombinants.
CV-1 cells were grown to 70–80% confluence in 60 mm
dishes. Confluent monolayers were washed once with PBS,
301P. Kumar et al. / Virology 366 (2007) 293–303followed by a two washes with 1 ml DME containing no FBS or
antibiotics. The culture medium was removed and overlaid with
0.2 ml defective vaccinia virus (dVVL) (∼multiplicity of
infection is 1 pfu/cell) diluted in 0.6 ml DMEM for 1 h at 37 °C
in CO2, with shaking every 15 min. dVVL is derived from the
vaccinia virus Lister strain (ATCC VR-862; Ober et al., 2002,
and was titered in the complementing cell line RK44.20; Holzer
and Falkner, 1997). The supernatant was removed, replaced
with 2 ml DMEM containing no FBS or antibiotics and cells
were transfected with 5 μg pDD4-mh5/ORF6 using lipofecta-
mine reagent (Invitrogen, Carlsbad, CA, USA), according to the
manufacturer's protocol. After 3 days, advanced cytopathic
effect was evident and the cells were harvested and subjected to
Western blot analysis (see below) for determining ORF6
expression. Alternatively, the cells and culture supernatant
were harvested together and then subjected to three rounds of
freeze-thawing and clarified by centrifugation at 1500 rpm for
5 min. The supernatant, which constitute the P1 viral stock, was
used to infect fresh CV-1 cells after which the P2 viral stock was
harvested in the same manner and stored at −80 °C before use.
The P2 viral stock was titered in CV-1 cells. This approach of
dominant host range selection provides a stringent and time-
saving method for obtaining vaccinia recombinants carrying
foreign genes and has been described previously (Holzer et al.,
1998). The recombinant vaccinia virus expressing the SARS-
CoV S protein was previously generated using the same
methods (Lip et al., 2006).
Expression of viral proteins in mammalian cells and
co-immuoprecipitation experiments
The nsp8 gene was PCR amplified from the pRSET-nsp8
plasmid with the following pair of primers: nsp8_forward
(5′-CGGGATCCGGCACCATGGCTATTGCTTCAG-3′) and
nsp8_reverse (5′-CCGCTCGAGTCACTGTAGTTTAA-
CAGCTG-3′). The amplicon was digested with BamHI and
XhoI and cloned into compatible sites in the mammalian
expression pXJ40myc vector which contains a myc-tag at the
N-terminus for ease of detection. Typically, ∼1×106 cells Vero
E6 were plated on 6 cm dish and allowed to attach overnight and
then infected with ORF6 recombinant vaccinia virus at a
multiplicity of infection of 1. Infection media was replaced 1 h
post-infection and the cells were transfected with 1 ug of
pXJ40myc-nsp8 using lipofectamine reagent as described
above. The cells were harvested ∼16 h later and lysed in IP
buffer (50 mM Tris (pH 8.0), 150 mM NaCl, 0.5% NP40, 0.5%
deoxycholic acid, 0.005% SDS) and used in co-immunopreci-
pitation experiments as previously described (Tan et al., 2004c).
Briefly, the lysate was incubated with an anti-myc polyclonal
antibody (A14, Santa Cruz Biotechnology, Santa Cruz, CA,
USA) overnight at 4 °C, followed by adsorption onto a 50 μl
suspension of protein A-sepharose beads (Roche Molecular
Biochemicals). Beads were then washed 3 times with cold IP
buffer and subjected to Western blot analysis as previously
described. Primary antibodies used here were anti-myc mono-
clonal (9E10, Santa Cruz Biotechnology) and rabbit anti-ORF6
(PUP3, Abgent, San Diego, CA, USA).For co-immunoprecipitation experiments performed with
SARS-CoV infected Vero E6 cells, Vero E6 cells were plated in
25 cm2 flasks and infected with an isolate of SARS-CoV (strain
HKU39849) as previously described (Kaye et al., 2006). The
cells were harvest at 0 or 24 h.p.i. and the lysates were then
subjected to Western blot analysis and co-immunoprecipitation
experiments as described above. Anti-nsp8 monoclonal
(described below) and rabbit anti-ORF6 antibodies were used
for Western blot while rabbit anti-flag polyclonal (Sigma) or
rabbit anti-ORF6 antibodies were used for immunoprecipitation.
Immunofluorescence analysis
Indirect immunofluorescence was performed using SARS-
CoV infected Vero E6 cells as previously described (Tan et al.,
2004c). Briefly, Vero E6 cells were plated onto 4-well chamber
slides (Lab-Tek) and infected with an isolate of SARS-CoV
(strain HKU39849) as previously described (Kaye et al., 2006).
42 h post-infection, chamber slides were washed twice in
phosphate-buffered saline (PBS); cells were then fixed and
permeabilized with methanol for 5 min and subsequently
subjected to gamma-irradiation to neutralize infectivity of the
virus. Cells were then refixed with 4% paraformaldehyde and
permeabilized with 0.2% Triton X100. Blocking was done
using PBS with 1% bovine serum albumin (Sigma) and each
chamber was incubated with relevant and irrelevant control
antibodies before being washed with PBS+1% BSA several
times. Chamber slides were then incubated using FITC-
conjugated goat anti-mouse and rhodamine-conjugated goat
anti-rabbit secondary antibodies (1:200; Santa Cruz) before
being washed again and mounted using glass coverslips and a
mixture of Fluorsave mounting medium (Calbiochem) and
Vectashield mounting medium with DAPI (Vector Labora-
tories). Imaging was done with an Olympus Fluoview upright
confocal microscope (Olympus).
Antibodies for detecting endogenous AP-1 and the FLAG
epitope were purchased from Sigma and antibodies against
LAMP-1 and LAMP-2 were purchased from Abcam plc. The
anti-GAL4TA antibody was purchased from Santa Cruz.
Monoclonal antibody against the nsp8 protein was prepared
as follows: bacterially expressed glutathione S-transferase
(GST)-nsp8 fusion protein was used to immunize BALB/c
mice as previously described (Fielding et al., 2004). The
spleen was excised from a mouse that showed strong antibody
response and hybridoma fusion was performed to generate
hybridomas producing monoclonal anti-nsp8 antibodies as
previously described (Lip et al., 2006). All procedures on the
use of laboratory animals were performed by trained personnel
in accordance with the regulations and guidelines of the
National Advisory Committee for Laboratory Animal
Research (NACLAR), Singapore. The culture supernatants
from several of these hybridoma clones were pooled and
purified using a HiTrap protein G HP column (Amersham)
and verified by immunofluoresence assay to be specific to the
nsp8 protein.
The mouse monoclonal primary antibodies (mouse anti-nsp8
and anti-GAL4TA) were used at concentrations of 0.2 mg/ml
302 P. Kumar et al. / Virology 366 (2007) 293–303and the rabbit polyclonal antibodies (anti-ORF6 and anti-flag)
were used at concentrations of 0.0025 mg/ml. Identical dilutions
of secondary antibodies were used for all samples.
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